FDA clears LivaNova aura6000 for moderate to severe sleep apnea

LivaNova said its aura6000 system won U.S. FDA premarket approval on March 18, 2026, for adults with moderate to severe obstructive sleep apnea, defined as an apnea-hypopnea index of 15 to 65, who have failed, can’t tolerate, or aren’t eligible for standard treatments including PAP, oral appliances, or pharmacotherapy. The implantable device uses proximal hypoglossal nerve stimulation, and the FDA’s approval record shows the indication does not require drug-induced sleep endoscopy for patient selection. In the pivotal OSPREY trial, the primary responder rate at seven months was 58.2% in the treatment arm versus 13.5% in controls, and the response rate in the original treatment arm rose to 64.6% after 13 months of follow-up. (accessdata.fda.gov)

Why it matters: For clinicians following sleep medicine and airway device regulation, aura6000 adds another FDA-approved hypoglossal nerve stimulation option, but with a potentially broader practical label than existing approaches. FDA documents state patients with complete concentric collapse were not excluded from clinical studies, and DISE was not required for selection, although CCC-specific outcomes were not separately analyzed. The approved device is not MRI-compatible, and FDA has already listed two post-approval study requirements, including continued OSPREY follow-up and a new enrollment study. More broadly, it also fits into a wider FDA pattern of backing implantable neuromodulation platforms in hard-to-treat conditions: for example, Nia Therapeutics recently received Breakthrough Device designation for a fully implantable, closed-loop neurostimulation system for episodic memory loss after moderate to severe traumatic brain injury, underscoring continued regulatory interest in targeted brain and nerve stimulation technologies. (accessdata.fda.gov; PharmaShots)

What to watch: LivaNova says it expects a next-generation, MRI-compatible version to launch in the first half of 2027, pending review of a PMA supplement by FDA. In the broader neuromodulation space, Nia has said it plans to file an IDE in 2026 for its memory-loss system, a reminder that FDA’s device pipeline is also expanding beyond sleep apnea into closed-loop neurostimulation applications. (nasdaq.com; PharmaShots)